What question did this study set out to answer?

To summarize current evidence and guidelines on neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer from a surgical viewpoint.

April 3, 2026CancersOpen Access

Surgical Perspectives on Neoadjuvant Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer

View Full Paper

Ask AI

Bookmark

To summarize current evidence and guidelines on neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer from a surgical viewpoint.
Conducted a structured narrative review of relevant studies and guidelines.
Emphasized pretreatment classification, medical imaging, and surgical strategies.
Analyzed outcomes post-neoadjuvant therapy and surgical management.
Neoadjuvant therapy is favored for borderline resectable and standard for locally advanced pancreatic cancer.
Surgical exploration is based on physiological recovery and the absence of metastatic progression.
NAT does not worsen short-term postoperative outcomes, but anticoagulation practices are inconsistent.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This narrative review explores neoadjuvant therapy's role in pancreatic cancer, suggesting improved surgical outcomes.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/69cf5ced5a333a821460a730 https://doi.org/10.3390/cancers18071131

View Full Paper

Ask AI

Bookmark

Surgical Perspectives on Neoadjuvant Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer

Key Points

Discussion

Implication

Cite This Study

Surgical Perspectives on Neoadjuvant Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider